Kyoto University · Medicine
Professor Yuji Nakamoto's research lab specializes in molecular imaging, particularly positron emission tomography (PET) using fluorodeoxyglucose (FDG) and other radiotracers. The lab focuses on optimizing PET/CT imaging protocols, improving quantitative accuracy in PET analysis, and enhancing the detection and differentiation of malignant and benign lesions in various cancers, including pancreatic and ovarian malignancies. Their work also investigates technical challenges such as attenuation correction methods and the impact of contrast agents on PET image quantification. The lab's research contributes significantly to improving diagnostic accuracy and patient follow-up strategies in oncology.
Figures are computed from collected data and may differ slightly.
Intense FDG uptake was usually observed in the palatine tonsils, lingual tonsils, and soft palate, whereas uptake in the major salivary glands was variable.
The current data suggest that delayed FDG-PET scanning at 2 hours postinjection may contribute to differentiation between malignant and benign lesions in the pancreas.
Although quantitative radioactivity values are generally comparable between CT- and germanium-corrected emission PET images, CT-based attenuation correction produced radioactivity concentration values significantly higher than the germanium-based corrected values. These effects, especially in radiodense tissues, should be noted when using and comparing quantitative PET analyses from PET and PET/CT systems.
Our preliminary data suggest that whole-body PET with FDG can be a complementary modality for following up patients who have had ovarian cancer, especially patients believed to be at risk for recurrence.
High concentrations of a contrast agent caused considerable overestimation of apparent tracer activity in phantom studies; however, the emission bias was relatively modest in vivo, except in areas with very high contrast agent concentrations.
PURPOSE: To retrospectively evaluate lesion findings at computed tomography (CT) performed as part of a combined positron emission tomography (PET)/CT examination in patients suspected of having metastatic bone lesions—lesions that were detected with fluorine 18 fluorodeoxyglucose (FDG) PET as part of the same examination—and to correlate the CT and FDG PET findings. MATERIALS AND METHODS: This HIPAA-compliant study had institutional review board approval, and the need for patient informed conse
Our preliminary data indicate that NIS-based gene therapy may be applied by concentrating a lethal dose of radiation in tumor cells in vivo, but further investigation is necessary to determine a method of maintaining radioiodine in the cells to allow greater therapeutic effects.
The most frequent pattern of detectable bone metastases with FDG-PET imaging was multiple foci of intense uptake. PET revealed more lesions than did bone scanning, independent of the type of cancer or location of bone involvement, in patients who were accurately diagnosed by FDG-PET imaging.
Open papers in the app to read, cite, and organize with AI.
